Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
[68Ga]BED003 injection
Blue Earth Diagnostics Ireland Ltd
Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
1 trial -
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Regeneron UK Limited
Macular Degeneration
1 trial -
anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection
Bristol-Myers Squibb Australia Pty Ltd
Advanced solid tumors
1 trial -
florquinitau F-18, VIZAMYL 400 MBq/mL solution for injection, [18F]PI-2620
The George Institute
cognitive impairment
1 trial -
placebo PH20 SC PFS, Vyvgart 1 000 mg solution for injection in pre-filled syringe
argenx
Systemic Sclerosis
1 trial -
rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada
Dompe' Farmaceutici S.p.A.
Dry Eye
1 trial -
sham group will undergo a procedure that will closely mimic the active injection but with no penetration of the globe.
Laboratoire HRA Pharma
Retinitis Pigmentosa
1 trial -
sham group will undergo a procedure that will closely mimic the active injection but with no penetration of the globe.
Laboratoire HRA Pharma
Retinitis Pigmentosa
1 trial -
sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.
The George Institute
Merkel Cell Carcinoma
1 trial -
sotatercept, PL1 - Powder for injection
Lacuna Pharma Pty Ltd
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
1 trial -
teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
14028 injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Type 2 Diabetes
1 trial -
15NH4Cl, Sodium Chloride for injection, [13C]Sodium Acetate, CMP-CPS-001
Camp4 Therapeutics Corp
Urea cycle disorders (UCD)
1 trial -
304 injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
CD20 Positive B Cell NHL
1 trial -
9MW3811 injection
Shanghai University of Traditional Chinese Medicine
Pulmonary Fibrosis
1 trial -
A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Lacuna Pharma Pty Ltd
not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)
1 trial -
A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants with Advanced Rod Cone Dystrophy
Pari Pharma GmbH
End-stage rod-cone dystrophy
1 trial -
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIRยฎ LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
Laboratorios Tillomed Spain S.L.U
Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps
1 trial -
A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167
Lacuna Pharma Pty Ltd
Chronic Heart Failure
1 trial -
A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants
Janssen-Cilag International N.V.
Tuberculosis
1 trial -
A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis
Hoffmann-La Roche
Multiple Sclerosis (MS)
1 trial -
A bioavailability study of epinephrine following a single dose of emergency response auto-injector in comparison to epinephrine injection into muscle via syringe in healthy adults.
Mylan Pharma UK
Allergic reactions (Type 1), including anaphylaxis, idiopathic anaphylaxis or exercise-induced anaphylaxis
1 trial -
A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis
Philogen S.p.A.
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
1 trial -
A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.
Lacuna Pharma Pty Ltd
Idiopathic pulmonary fibrosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources